Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma (TRI Pro)

2 novembre 2026 aggiornato da: Janssen Research & Development, LLC

Phase 2 Randomized, Double-blind, Placebo-controlled Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig, compared to participants who receive placebo. CRS is an acute inflammatory reaction that can occur during treatment and may be associated with flu-like or other systemic symptoms, such as fever and tiredness.

Panoramica dello studio

Stato

Reclutamento

Condizioni

Tipo di studio

Interventistico

Iscrizione (Stimato)

230

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

      • Buenos Aires, Argentina, C1199ABB
        • Reclutamento
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Argentina, C1426ANZ
        • Reclutamento
        • Instituto Alexander Fleming
      • Buenos Aires, Argentina, C1118
        • Reclutamento
        • Hospital Aleman
      • Córdoba, Argentina, X5016KEH
        • Reclutamento
        • Hospital Privado Centro Medico de Cordoba
      • Pilar, Argentina, 1629
        • Reclutamento
        • Hospital Universitario Austral
      • Bedford Park, Australia, 5042
        • Reclutamento
        • Flinders Medical Centre
      • Birtinya, Australia, 4575
        • Reclutamento
        • Sunshine Coast University Hospital
      • Concord, Australia, 2139
        • Reclutamento
        • Concord Repatriation General Hospital
      • Fitzroy, Australia, 3065
        • Reclutamento
        • St Vincents Hospital Melbourne
      • Wollongong, Australia, 2500
        • Reclutamento
        • Wollongong Hospital
      • Argenteuil, Francia, 95107
        • Reclutamento
        • Centre Hospitalier Victor Dupouy
      • Bayonne, Francia, 64100
        • Reclutamento
        • Centre Hospitalier de la Cote Basque
      • La Tronche, Francia, 38700
        • Reclutamento
        • CHU de Grenoble
      • Le Mans, Francia, 72100
        • Reclutamento
        • Centre de Cancerologie de la Sarthe
      • Nantes, Francia, 44000
        • Reclutamento
        • CHU Nantes - Hotel Dieu
      • Quimper, Francia, 29000
        • Reclutamento
        • Centre Hospitalier de Quimper Cornouaille
      • Alexandroupoli, Grecia, 681 00
        • Reclutamento
        • Uni General Hospital of Alexandroupolis
      • Athens, Grecia, 11528
        • Reclutamento
        • Alexandra General Hospital of Athens
      • Athens, Grecia, 115 25
        • Reclutamento
        • 251 Air Force General Hospital
      • Piraeus, Grecia, 18537
        • Reclutamento
        • Metaxa Cancer Center Hospital Of Piraeus
      • Rio, Grecia, 265 04
        • Reclutamento
        • General University Hospital of Patras
      • Thessaloniki, Grecia, 54642
        • Reclutamento
        • Hippokration Hospital
      • Thessaloniki, Grecia, 546 39
        • Reclutamento
        • Theageneio Cancer Hospital
      • Ampang, Malaysia, 68000
        • Reclutamento
        • Hospital Ampang
      • George Town, Malaysia, 10450
        • Reclutamento
        • Hospital Pulau Pinang
      • Johor Bharu, Malaysia, 80100
        • Reclutamento
        • Hospital Sultanah Aminah
      • Kota Kinabalu, Malaysia, 88586
        • Reclutamento
        • Hospital Queen Elizabeth
      • Kuching, Malaysia, 93586
        • Reclutamento
        • Sarawak General Hospital
      • Braga, Portogallo, 4710 243
        • Reclutamento
        • Uls Braga - Hosp. Braga
      • Lisbon, Portogallo, 1099 023
        • Reclutamento
        • Ipo Lisboa
      • Lisbon, Portogallo, 1998 018
        • Reclutamento
        • Hosp. Cuf Descobertas
      • Porto, Portogallo, 4200 319
        • Reclutamento
        • Uls Sao Joao - Hosp. Sao Joao
      • Porto, Portogallo, 4050 342
        • Reclutamento
        • Uls Santo Antonio - Hosp. Santo Antonio
      • Vila Nova de Gaia, Portogallo, 4434 502
        • Reclutamento
        • Uls Gaia Espinho
      • Barcelona, Spagna, 08041
        • Reclutamento
        • Hosp. de La Santa Creu I Sant Pau
      • León, Spagna, 24071
        • Reclutamento
        • Hosp. de Leon
      • Madrid, Spagna, 28046
        • Reclutamento
        • Hosp. Univ. La Paz
      • Madrid, Spagna, 28055
        • Reclutamento
        • Hosp. Blua Sanitas Valdebebas
      • Málaga, Spagna, 29010
        • Reclutamento
        • Hosp Regional Univ de Malaga
      • Pamplona, Spagna, 31008
        • Reclutamento
        • Hosp. de Navarra
      • Valencia, Spagna, 46017
        • Reclutamento
        • Hosp. Univ. Dr. Peset
    • Arizona
      • Goodyear, Arizona, Stati Uniti, 85338
        • Reclutamento
        • City of Hope Phoenix
    • California
      • Beverly Hills, California, Stati Uniti, 90211
        • Reclutamento
        • Beverly Hills Cancer Center (BHCC)
      • Irvine, California, Stati Uniti, 92618
        • Reclutamento
        • City of Hope Orange County Lennar Foundation Cancer Center
      • Palo Alto, California, Stati Uniti, 94304
        • Reclutamento
        • Stanford University Medical Center
    • Colorado
      • Denver, Colorado, Stati Uniti, 80218
        • Reclutamento
        • Colorado Blood Cancer Institute
    • Missouri
      • St Louis, Missouri, Stati Uniti, 63110
        • Reclutamento
        • Washington University School Of Medicine
    • Ohio
      • Columbus, Ohio, Stati Uniti, 43214
        • Reclutamento
        • Ohio Health Research Institute
    • Tennessee
      • Nashville, Tennessee, Stati Uniti, 37203
        • Reclutamento
        • Sarah Cannon Research Institute
    • Utah
      • Salt Lake City, Utah, Stati Uniti, 84112
        • Reclutamento
        • University of Utah Huntsman Cancer Institute
      • Falun, Svezia, 791 82
        • Reclutamento
        • Falu Lasarett Medicinkliniken Falun
      • Gothenburg, Svezia, 413 45
        • Reclutamento
        • Sahlgrenska Universitetssjukhuset
      • Lund, Svezia, 221 85
        • Reclutamento
        • Skanes universitetssjukhus
      • Stockholm, Svezia, 141 86
        • Reclutamento
        • Karolinska University Hospital Huddinge
      • Uppsala, Svezia, 752 37
        • Reclutamento
        • Akademiska Sjukhuset
      • Budapest, Ungheria, 1088
        • Reclutamento
        • Semmelweis Egyetem
      • Budapest, Ungheria, 1097
        • Reclutamento
        • Del Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet Szent Laszlo Telephely
      • Budapest, Ungheria, 1122
        • Reclutamento
        • Orszagos Onkologiai Intezet
      • Pécs, Ungheria, 7624
        • Reclutamento
        • Pecsi Tudomanyegyetem Klinikai Kozpont
      • Szeged, Ungheria, 6725
        • Reclutamento
        • Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion criteria:

  • Documented diagnosis of multiple myeloma (MM) as defined by the criteria: a. MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria; b. Measurable disease at screening as assessed by local laboratory as defined in the protocol
  • Received at least 1 prior lines of antimyeloma therapy
  • Relapsed or refractory disease as defined: a. Relapsed disease is defined as an initial response to prior treatment, followed by confirmed progressive disease (PD) by the IMWG response criteria greater than (>) 60 days after cessation of treatment.; b. Refractory disease is defined as failure to achieve a response or confirmed PD by the IMWG response criteria during previous treatment or less than or equal to (<=) 60 days after cessation of treatment
  • Have an eastern cooperative oncology group (ECOG) performance status (PS) score of 0 to 2 at screening and immediately before the start of study treatment administration. Participants with ECOG PS 2 or 3 are eligible for the study if the ECOG PS score is related to stable physical limitations (example, wheelchair-bound due to prior spinal cord injury) and not related to MM or associated therapy
  • Have clinical laboratory values meeting the criteria specified in the protocol

Exclusion criteria:

  • Concurrent use of any other anticancer treatment (including non-palliative radiotherapy) or investigational agent
  • Major surgery, (for example, requiring general anesthesia) within 2 weeks before first dose, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study
  • Suspected or known allergies, hypersensitivity, or intolerance to ramantamig and tocilizumab or their excipients
  • Presence of any of the following: a. Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM); b. Any history of malignancy, other than MM, that is considered at high risk of recurrence requiring systemic therapy; c. Any active malignancy other than MM
  • Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM. If either is suspected, negative whole brain magnetic resonance imaging (MRI) and lumbar cytology are required

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Prevenzione
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Arm A: Tocilizumab + Ramantamig

Participants will receive tocilizumab along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until progressive disease (PD) or intolerable toxicity (whichever is earlier).

Ramantamig will be administered as subcutaneous (SC) injection.

Altri nomi:
  • JNJ-79635322

Tocilizumab will be administered as intravenous (IV) injection.

Comparatore placebo: Arm B: Placebo + Ramantamig

Participants will receive placebo (saline) along with ramantamig. Ramantamig will be administered for a total treatment of finite duration, or until PD or intolerable toxicity (whichever is earlier).

Ramantamig will be administered as subcutaneous (SC) injection.

Altri nomi:
  • JNJ-79635322

Placebo (saline) will be administered as IV injection.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS)
Lasso di tempo: By the end of Day 28 from first ramantamig dose

Percentage of participants alive and free of treatment-emergent ASTCT Grade >=2 CRS without the use of intervening treatment for CRS of any grade by the end of day 28 from first ramantamig dose will be reported.

By the end of Day 28 from first ramantamig dose

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the End of Day 28 from First Ramantamig Dose
Lasso di tempo: By the end of Day 28 from first ramantamig dose

Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 by the end of day 28 from first ramantamig dose, respectively, will be reported.

By the end of Day 28 from first ramantamig dose
Percentage of Participants with Treatment-Emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 During Ramantamig Treatment
Lasso di tempo: Up to 38 months

Percentage of participants with treatment-emergent CRS of any ASTCT Grade, Grade >=2, and Grade >=3 during ramantamig treatment will be reported.

Up to 38 months
Percentage of Participants with Re-occurrence of CRS with ASTCT Grade >=2 After the Initial Occurrence of Treatment-Emergent Grade >=2 CRS Event
Lasso di tempo: Up to 38 months

Percentage of participants with re-occurrence of CRS with ASTCT Grade >=2 after the initial occurrence of treatment-emergent Grade >=2 CRS event will be reported.

Up to 38 months
Percentage of Participants with Re-occurrence of CRS for All Grades
Lasso di tempo: Up to 38 months

Percentage of participants with re-occurrence of CRS for all Grades will be reported.

Up to 38 months
Overall Response
Lasso di tempo: Up to 38 months

Overall response is defined as the percentage of participants who achieve partial response (PR) or better prior to progressive disease (PD) or subsequent antimyeloma therapy, in accordance with the international myeloma working group (IMWG) criteria.

Up to 38 months
Complete Response (CR) or Better
Lasso di tempo: Up to 38 months

CR or better rate is defined as the percentage of participants achieving CR or stringent complete response (sCR) prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria.

Up to 38 months
Very Good Partial Response (VGPR) or Better
Lasso di tempo: Up to Month 38

VGPR or better rate is defined as the percentage of participants achieving VGPR, CR or sCR prior to PD or subsequent antimyeloma therapy, in accordance with the IMWG criteria.

Up to Month 38
Duration of Response (DoR)
Lasso di tempo: Up to 38 months

DoR is defined as the time interval between the date of initial documentation of a response (PR or better) to the date of first documented evidence of PD according to the IMWG response criteria or death due to any cause, whichever occurs first.

Up to 38 months
Time to Response (TTR)
Lasso di tempo: Up to 38 months

TTR is defined as the time from the date of randomization to the date of first documentation of a confirmed response (PR or better) for participants who have PR or better as their best response.

Up to 38 months
Progression-Free Survival (PFS)
Lasso di tempo: Up to Month 38

PFS is defined as the duration from the date of randomization to either PD or death, whichever comes first. Disease progression will be determined according to the IMWG response criteria.

Up to Month 38
Time to Subsequent Antimyeloma Therapy
Lasso di tempo: Up to Month 38

Time to subsequent antimyeloma therapy is defined as the time from randomization to the start of subsequent antimyeloma treatment. Death due to progressive disease without the start of any subsequent antimyeloma therapy will be considered as an event.

Up to Month 38
Percentage of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity
Lasso di tempo: Up to 38 months

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. Any new or worsening AE occurring at or after the initial administration of study treatment through the day of last dose plus 30 days or prior to the start of subsequent antimyeloma therapy, whichever is earlier, or any follow-up AE (linked to an existing TEAE) with onset date and time beyond 30 days after the last dose of study treatment but prior to the start of subsequent therapy, or any AE that is considered treatment-related regardless of the start date of the event, is considered to be treatment-emergent. TEAEs will be graded according to the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 6.0. Severity scale ranges from Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening, Grade 5= death related to adverse event.

Up to 38 months
Percentage of Participants with Abnormalities in Laboratory Parameters
Lasso di tempo: Up to 38 months

Percentage of participants with abnormalities in laboratory parameters (serum chemistry and hematology) will be reported.

Up to 38 months
Percentage of Participants with Incidence of Adverse Events of Clinical Interests
Lasso di tempo: Up to 38 Months

Percentage of participants with incidence of adverse events of clinical interests such as cytopenia will be reported.

Up to 38 Months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

30 giugno 2026

Completamento primario (Stimato)

31 dicembre 2027

Completamento dello studio (Stimato)

30 luglio 2030

Date di iscrizione allo studio

Primo inviato

11 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

11 maggio 2026

Primo Inserito (Effettivo)

15 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

3 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

Sì

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi